Zoetis (ZTS) : $14.06 million worth of transactions were on upticks in Zoetis (ZTS), compared to $10.31 million on downticks. The ratio between the two was 1.36, whereas, the net money flow stood at a healthy $3.75 million on Tuesdays session. The consistent buying on upticks in the stock accounted for $4.3million worth of trades. The total money flow into the stock stood at $4.3 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.05%. The stock was trading at $50.74, with a drop of $0.03 over the previous days close. The stock recorded -0.05% for the week.
Also, Barclays maintains their rating on the shares of Zoetis (NYSE:ZTS). The current rating of the shares is Equal-weight. Equity Analysts at the Firm raises the price target to $49 per share from $45 per share. The rating by the firm was issued on August 4, 2016.
Zoetis Inc. has dropped 0.98% in the last five trading days, however, the shares have posted positive gains of 0.69% in the last 4 weeks. Zoetis Inc. is up 6.28% in the last 3-month period. Year-to-Date the stock performance stands at 6.58%.
Zoetis (NYSE:ZTS): The stock opened at $50.68 on Tuesday but the bulls could not build on the opening and the stock topped out at $50.90 for the day. The stock traded down to $50.37 during the day, due to lack of any buying support eventually closed down at $50.75 with a loss of -0.02% for the day. The stock had closed at $50.76 on the previous day. The total traded volume was 2,878,680 shares.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.